Jefferies Says Watch for Bottom in Endo Pharma (ENDP)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- The Israeli Air Force Has Completed Its Preparation For An Imminent Attack Against Iran - Reuters
- Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending dose study for BHV-1300
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
- Nike, Alpine Immune Sciences rise premarket; CarMax, Robinhood and Regeneron fall
- After-hours movers: Alpine Immune Sciences, Costco, and more
- Midday movers: Delta, Taiwan Semiconductor rise; Hexcel falls
Endo Pharmaceuticals Holdings (ENDP) Tops Q3 EPS by 2c; Adjusts FY12 Outlook
November 5, 2012 7:04 AM ESTEndo Pharmaceuticals Holdings (NASDAQ: ENDP) reported Q3 EPS of $1.28, $0.02 better than the analyst estimate of $1.26. Revenue for the quarter came in at $750 million versus the consensus estimate of $788.53 million.
Sees FY2012 EPS of $5.00-$5.10, versus the consensus of $5.03. Endo Pharmaceuticals Holdings sees FY2012... More
